Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease

References

• Aldinucci D, Colombatti A. 2014. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014:292376.
   PubMed Web of Science ®Google Scholar
• Alfaro C, Teijeira A, Oñate C, Pérez G, Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A, Rodriguez-Paulete A, et al. 2016. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs). Clinical Cancer Res. 22(15):3924–36.
   PubMed Web of Science ®Google Scholar
• Åström M, Tajeddinn W, Karlsson MG, Linder O, Palmblad J, Lindblad P. 2018. Cytokine measurements for diagnosing and characterizing leukemoid reactions and immunohistochemical validation of a granulocyte colony-stimulating factor and CXCL8-producing renal cell carcinoma. Biomark Insights. 13:1177271918792246.
   Web of Science ®Google Scholar
• Barash U, Zohar Y, Wildbaum G, Beider K, Nagler A, Karin N, Ilan N, Vlodavsky I. 2014. Heparanase enhances myeloma progression via CXCL10 downregulation. Leukemia. 28(11):2178–87.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Nepstad I, Bruserud Ø. 2017. Mesenchymal stem cells support survival and proliferation of primary human acute myeloid leukemia cells through heterogeneous molecular mechanisms. Front Immunol. 8:106.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Reikvam BØ. 2016. A subset of patients with acute myeloid leukemia has leukemia cells characterized by chemokine responsiveness and altered expression of transcriptional as well as angiogenic regulators. Front Immunol. 7:205.
   PubMed Web of Science ®Google Scholar
• Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stöckel A, Avril S, Kiechle M, Schmitt M. 2012. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. BCR. 14(1):R30.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, Arcese W, Amadori S, Venditti A. 2012. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 119(2):332–41.
   PubMed Web of Science ®Google Scholar
• Carvalheiro T, Horta S, JAG VR, Santiago M, Salvador MJ, Trindade H, Radstake TRDJ, JAP DS, Paiva A. 2018. Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients. Inflammation Res. 67:169–77.
   PubMed Web of Science ®Google Scholar
• Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P, et al. 2016. CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res. 76(19):5671–82.
   PubMed Web of Science ®Google Scholar
• Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, Peng HM, Chu YY, Chiang JM, Dutta A, et al. 2012. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 72(5):1092–102.
   PubMed Web of Science ®Google Scholar
• Chheda ZS, Sharma RK, Jala VR, Luster AD, Haribabu B. 2016. Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors. J Immunol. 197(5):2016–26.
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. 2014. Chemokines in cancer. Cancer Immuno Re. 2(12):1125–31.
   PubMed Web of Science ®Google Scholar
• Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, Craddock C, Malladi R, Moss PA. 2012. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood. 120(20):4246–55.
   PubMed Web of Science ®Google Scholar
• De Larco JE, Wuertz BR, Furcht LT. 2004. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clinical Cancer Res. 10(15):4895–900.
   PubMed Web of Science ®Google Scholar
• Degos C, Heinemann M, Barrou J, Boucherit N, Lambaudie E, Savina A, Gorvel L, Olive D. 2019. Endometrial tumor microenvironment alters human NK cell recruitment, and resident NK cell phenotype and function. Front Immunol. 10:877.
   PubMed Web of Science ®Google Scholar
• Dell’Agnola C, Biragyn A. 2007. Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines. 6(2):267–83.
   PubMed Web of Science ®Google Scholar
• Dickinson AM, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, Kolb HJ. 2017. Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia. Front Immunol. 8:496.
   PubMed Web of Science ®Google Scholar
• Dominguez C, McCampbell KK, David JM, Palena C. 2017. Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer. JCI Insight. 2:21.
   Web of Science ®Google Scholar
• Duarte D, Amarteifio S, Ang H, Kong IY, Ruivo N, Pruessner G, Hawkins ED, Lo Celso C. 2019. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging. Immunol Cell Biol. 97(2):229–35.
   PubMed Web of Science ®Google Scholar
• Ferreira AM, Rollins BJ, Faunce DE, Burns AL, Zhu X, Dipietro LA. 2005. The effect of MCP-1 depletion on chemokine and chemokine-related gene expression: evidence for a complex network in acute inflammation. Cytokine. 30(2):64–71.
   PubMed Web of Science ®Google Scholar
• Floros T, Tarhini AA. 2015. Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 42(4):539–48.
   PubMed Web of Science ®Google Scholar
• Franciszkiewicz K, Boissonnas A, Boutet M, Combadière C, Mami-Chouaib F. 2012. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 72(24):6325–32.
   PubMed Web of Science ®Google Scholar
• Fredly H, Reikvam H, Gjertsen BT, Bruserud O. 2012. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol. 87(4):368–76.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. 2012. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology. 1(7):1111–34.
   PubMed Web of Science ®Google Scholar
• Guirnalda P, Wood L, Goenka R, Crespo J, Paterson Y. 2013. Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with listeria monocytogenes. Oncoimmunology. 2(8):e25752.
   PubMed Web of Science ®Google Scholar
• Halama N, Zoernig I, Berthel A, Kahlert C, Klupp F, Suarez-Carmona M, Suetterlin T, Brand K, Krauss J, Lasitschka F, et al. 2016. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by Anti-CCR5 therapy in cancer patients. Cancer Cell. 29(4):587–601.
   PubMed Web of Science ®Google Scholar
• Hantschel O, Gstoettenbauer A, Colinge J, Kaupe I, Bilban M, Burkard TR, Valent P, Superti-Furga G. 2008. The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol Oncol. 2(3):272–81.
   PubMed Web of Science ®Google Scholar
• He S, Cao Q, Qiu Y, Mi J, Zhang JZ, Jin M, Ge H, Emerson SG, Zhang Y, Zhang Y. 2008. A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody. J Immunol. 181(11):7581–92.
   PubMed Web of Science ®Google Scholar
• Hu Z, Chen J, Zhou S, Yang N, Duan S, Zhang Z, Su J, He J, Zhang Z, Lu X, et al. 2017. Mouse IP-10 gene delivered by folate-modified chitosan nanoparticles and dendritic/tumor cells fusion vaccine effectively inhibit the growth of hepatocellular carcinoma in mice. Theranostics. 7(7):1942–52.
   PubMed Web of Science ®Google Scholar
• Huang H, Liu Y, Xiang J. 2002. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol. 217(1–2):12–22.
   PubMed Web of Science ®Google Scholar
• Huang J, Liu Y, Au BC, Barber DL, Arruda A, Schambach A, Rothe M, Minden MD, Paige CJ, Medin JA. 2016. Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML. Mol Ther Methods Clin Dev. 3:16074.
   PubMed Web of Science ®Google Scholar
• Hughes CE, Nibbs RJ. 2018. A guide to chemokines and their receptors. Febs J. 285(16):2944–71.
   PubMed Web of Science ®Google Scholar
• Jedlickova Z, Schmid C, Koenecke C, Hertenstein B, Baurmann H, Schwerdtfeger R, Tischer J, Kolb HJ, Schleuning M. 2016. Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 51(5):663–67.
   PubMed Web of Science ®Google Scholar
• Kang TH, Kim KW, Bae HC, Seong SY, Kim TW. 2011. Enhancement of DNA vaccine potency by antigen linkage to IFN-γ-inducible protein-10. Int J Cancer. 128(3):702–14.
   PubMed Web of Science ®Google Scholar
• Karin N, Wildbaum G. 2015. The role of chemokines in shaping the balance between CD4(+) T cell subsets and its therapeutic implications in autoimmune and cancer diseases. Frontier Immuno. 6:609.
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK. 2006. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol. 177(10):6962–73.
   PubMed Web of Science ®Google Scholar
• Kitamura T, Qian BZ, Soong D, Cassetta L, Noy R, Sugano G, Kato Y, Li J, Pollard JW. 2015. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J Exp Med. 212(7):1043–59.
   PubMed Web of Science ®Google Scholar
• Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, Couriel DR, Martin PJ, Flowers ME, Hansen JA, et al. 2014. CXCL9 elevations correlate with chronic GVHD diagnosis. Blood. 123(5):786–93.
   PubMed Web of Science ®Google Scholar
• Kittang AO, Sand K, Brenner AK, Rye KP, Bruserud Ø. 2016. The systemic profile of soluble immune mediators in patients with myelodysplastic syndromes. Int J Mol Sci. 17:7.
   Web of Science ®Google Scholar
• Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. 2013. Cytokine levels in the serum of healthy subjects. Mediators Inflammatory. 2013:434010.
   PubMed Web of Science ®Google Scholar
• Klinke DJ 2nd. 2015. Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: interleukin-12 as a case study. J ImmunoTher Cancer. 3:27.
   PubMed Web of Science ®Google Scholar
• Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. 2010. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood. 116(20):4251–61.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wang L, Wu K, Li W, Zhao E, Cui T, Wei S, Liu Y, Wang Y, Vatan L, et al. 2016. Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma. Oncoimmunology. 5(8):e1105430.
   PubMed Web of Science ®Google Scholar
• Kuett A, Rieger C, Perathoner D, Herold T, Wagner M, Sironi S, Sotlar K, Horny HP, Deniffel C, Drolle H, et al. 2015. IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia. Sci Rep. 5:18411.
   PubMed Web of Science ®Google Scholar
• Kumamoto T, Huang EK, Paek HJ, Morita A, Matsue H, Valentini RF, Takashima A. 2002. Induction of tumor-specific protective immunity by in situ langerhans cell vaccine. Nat Biotechnol. 20(1):64–69.
   PubMed Web of Science ®Google Scholar
• Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD, et al. 2012. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer. 106(11):1833–41.
   PubMed Web of Science ®Google Scholar
• Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E. 2008. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer. 123(9):2031–40.
   PubMed Web of Science ®Google Scholar
• Levine JE, Logan BR, Wu J, Alousi AM, Bolaños-Meade J, Ferrara JL, Ho VT, Weisdorf DJ, Paczesny S. 2012. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a blood and marrow transplant clinical trials network study. Blood. 119(16):3854–60.
   PubMed Web of Science ®Google Scholar
• Li B, Li Q, Zhao QL, Wei XB, Zhang XH, Wu CQ, Zhong CP. 2007. Murine dendritic cells modified with CXCL10 gene and tumour cell lysate mediate potent antitumour immune responses in mice. Scand J Immunol. 65(1):8–13.
   PubMed Web of Science ®Google Scholar
• Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, et al. 2017. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 66(1):157–67.
   PubMed Web of Science ®Google Scholar
• Lieber S, Reinartz S, Raifer H, Finkernagel F, Dreyer T, Bronger H, Jansen JM, Wagner U, Worzfeld T, Müller R, et al. 2018. Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells. Oncoimmunology. 7(5):e1424672.
   PubMed Web of Science ®Google Scholar
• Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, Stiles JK. 2011. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22(3):121–30.
   PubMed Web of Science ®Google Scholar
• Liubomirski Y, Lerrer S, Meshel T, Rubinstein-Achiasaf L, Morein D, Wiemann S, Körner C, Ben-Baruch A. 2019. Tumor-stroma-inflammation networks promote pro-metastatic chemokines and aggressiveness characteristics in triple-negative breast cancer. Front Immunol. 10:757.
   PubMed Web of Science ®Google Scholar
• Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ. 2007. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 67(19):9417–24.
   PubMed Web of Science ®Google Scholar
• Ma Z, Zhao X, Deng M, Huang Z, Wang J, Wu Y, Cui D, Liu Y, Liu R, Ouyang G. 2019. Bone marrow mesenchymal stromal cell-derived periostin promotes B-ALL progression by modulating CCL2 in leukemia cells. Cell Rep. 26(6):1533–1543.e4. doi: 10.1016/j.celrep.2019.01.034
   PubMed Web of Science ®Google Scholar
• Macanas-Pirard P, Quezada T, Navarrete L, Broekhuizen R, Leisewitz A, Nervi B, Ramírez PA. 2017. The CCL2/CCR2 axis affects transmigration and proliferation but not resistance to chemotherapy of acute myeloid leukemia cells. PLoS One. 12(1):e0168888.
   PubMed Web of Science ®Google Scholar
• Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P. 2007. Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial. Cancer Gene Ther. 14(8):717–23.
   PubMed Web of Science ®Google Scholar
• Mazur G, Wróbel T, Butrym A, Kapelko-Słowik K, Poreba R, Kuliczkowski K. 2007. Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. Neoplasma. 54(4):285–89.
   PubMed Web of Science ®Google Scholar
• Mikucki ME, Fisher DT, Matsuzaki J, Skitzki JJ, Gaulin NB, Muhitch JB, Ku AW, Frelinger JG, Odunsi K, Gajewski TF, et al. 2015. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 6:7458.
   PubMed Web of Science ®Google Scholar
• Murai M, Yoneyama H, Harada A, Yi Z, Vestergaard C, Guo B, Suzuki K, Asakura H, Matsushima K. 1999. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest. 104(1):49–57.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. 2017. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 17(9):559–72.
   PubMed Web of Science ®Google Scholar
• Naschberger E, Croner RS, Merkel S, Dimmler A, Tripal P, Amann KU, Kremmer E, Brueckl WM, Papadopoulos T, Hohenadl C, et al. 2008. Angiostatic immune reaction in colorectal carcinoma: impact on survival and perspectives for antiangiogenic therapy. Int J Cancer. 123(9):2120–29.
   PubMed Web of Science ®Google Scholar
• Nishikawa Y, Mochida K, Kubo T, Horikawa N, Nemoto R, Amano M. 2019. Smoldering type adult T-cell leukemia/lymphoma effectively treated with mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody) – a case report. Clin Case Rep. 7(5):1057–61.
   PubMed Web of Science ®Google Scholar
• Olsnes AM, Hatfield KJ, Bruserud Ø. 2009. The chemokine system and its contribution to leukemogenesis and treatment responsiveness in patients with acute myeloid leukemia. J B.u.o.n. 14(1):131–40.
   Google Scholar
• Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, Misek DE, Cooke KR, Kitko CL, Weyand A, et al. 2009. A biomarker panel for acute graft-versus-host disease. Blood. 113(2):273–78.
   PubMed Web of Science ®Google Scholar
• Padovan E, Spagnoli GC, Ferrantini M, Heberer M. 2002. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol. 71(4):669–76.
   PubMed Web of Science ®Google Scholar
• Palomino DC, Marti LC. 2015. Chemokines and immunity. Einstein (Sao Paulo). 13(3):469–73.
   PubMed Web of Science ®Google Scholar
• Pan Y, Smithson LJ, Ma Y, Hambardzumyan D, Gutmann DH. 2017. Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival. Oncotarget. 8(20):32977–89.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Tefferi A. 2012. Cytogenetic risk stratification in myelodysplastic syndromes: are we there yet? J Clin Oncol. 30(21):2703–04.
   PubMed Web of Science ®Google Scholar
• Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, et al. 2015. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature. 527(7577):249–53.
   PubMed Web of Science ®Google Scholar
• Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicholls S, Mahendra P, Craddock C, Moss PA. 2007. CXCL10-CXCR3 interactions play an important role in the pathogenesis of acute graft-versus-host disease in the skin following allogeneic stem-cell transplantation. Blood. 110(12):3827–32.
   PubMed Web of Science ®Google Scholar
• Piqueras B, Connolly J, Freitas H, Palucka AK, Banchereau J. 2006. Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. Blood. 107(7):2613–18.
   PubMed Web of Science ®Google Scholar
• Rashidi A, Uy GL. 2015. Targeting the microenvironment in acute myeloid leukemia. Curr Hematological Malignancy Rep. 10(2):126–31.
   PubMed Web of Science ®Google Scholar
• Rollins BJ. 2009. Where the confusion began: cloning the first chemokine receptors. J Immunol. 183(5):2893–94.
   PubMed Web of Science ®Google Scholar
• Rosenkilde MM, Schwartz TW. 2004. The chemokine system – a major regulator of angiogenesis in health and disease. APMIS. 112(7–8):481–95.
   PubMed Web of Science ®Google Scholar
• Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M. 2007. Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer. 109(12):2392–404.
   PubMed Web of Science ®Google Scholar
• Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. 2000. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood. 96(1):34–40.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Carranza-Rua O, Alfaro C, Oñate C, Martín-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, et al. 2014. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clinical Cancer Res. 20(22):5697–707.
   PubMed Web of Science ®Google Scholar
• Schiavo R, Baatar D, Olkhanud P, Indig FE, Restifo N, Taub D, Biragyn A. 2006. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood. 107(12):4597–605.
   PubMed Web of Science ®Google Scholar
• Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, et al. 2015. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood. 125(20):3144–52.
   PubMed Web of Science ®Google Scholar
• Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, et al. 2018. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the chronic malignancies working party of the European society of blood and marrow transplantation. Haematologica. 103(2):237–45.
   PubMed Web of Science ®Google Scholar
• Schulz C, von Andrian UH, Massberg S. 2009. Hematopoietic stem and progenitor cells: their mobilization and homing to bone marrow and peripheral tissue. Immunol Res. 44(1–3):160–68.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Taniguchi M, Street SE. 2000. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol. 165(5):2665–70.
   PubMed Web of Science ®Google Scholar
• Spranger S, Dai D, Horton B, Gajewski TF. 2017. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 8.31(5):711–723.e4. doi:10.1016/j.ccell.2017.04.003.
   PubMed Web of Science ®Google Scholar
• Stoll G, Pol J, Soumelis V, Zitvogel L, Kroemer G. 2018. Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts. Oncoimmunology. 7(10):e1484980.
   PubMed Web of Science ®Google Scholar
• Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS, Linehan DC. 2009. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 182(3):1746–55.
   PubMed Web of Science ®Google Scholar
• Thaiss CA, Semmling V, Franken L, Wagner H, Kurts C. 2011. Chemokines: a new dendritic cell signal for T cell activation. Front Immunol. 2:31.
   PubMed Web of Science ®Google Scholar
• van Attekum MHA, JAC VB, Slinger E, Lebre MC, Reinen E, Kersting S, Eldering E, Kater AP. 2017. CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. Haematologica. 102(12):2069–76.
   PubMed Web of Science ®Google Scholar
• Vilgelm AE, Richmond A. 2019. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol. 10:333.
   PubMed Web of Science ®Google Scholar
• Vogt V, Schick J, Ansprenger C, Braeu M, Kroell T, Kraemer D, Köhne CH, Hausmann A, Buhmann R, Tischer J, et al. 2014. Profiles of activation, differentiation- markers, or ß-integrines on T cells contribute to predict Tcells’ antileukemic responses after stimulation with leukemia-derived dendritic cells. J ImmunoTher. 6:331–47.
   Web of Science ®Google Scholar
• Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, Johnson MG, Medina JC, Collins TL, Fulton AM. 2006. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res. 66(15):7701–07.
   PubMed Web of Science ®Google Scholar
• Waugh DJ, Wilson C. 2008. The interleukin-8 pathway in cancer. Clinical Cancer Res. 14(21):6735–41.
   PubMed Web of Science ®Google Scholar
• Wong JL, Berk E, Edwards RP, Kalinski P. 2013. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res. 73(15):4653–62.
   PubMed Web of Science ®Google Scholar
• Wu SY, Yang J, Hong D, Xiao PF, Lu J, Gao L, Hu YX, Wang M, Shao XJ, Zhou CY, et al. 2018. Suppressed CCL2 expression inhibits the proliferation of leukemia cells via the cell cycle protein Cyclin D1: preliminary in vitro data. Eur Rev Med Pharmacol Sci. 22(17):5588–96.
   PubMed Web of Science ®Google Scholar
• Yoshimura T. 2018. The chemokine MCP-1 (CCL2) in the host interaction with cancer: a foe or ally? Cell Mol Immunol. 15(4):335–45.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Liu M, Chen X, Li L, Wang JM. 2015. Crosstalk between tumor cells and macrophages in stroma renders tumor cells as the primary source of MCP-1/CCL2 in lewis lung carcinoma. Front Immunol. 6:332.
   PubMed Web of Science ®Google Scholar
• Zhu YM, Woll PJ. 2005. Mitogenic effects of interleukin-8/CXCL8 on cancer cells. Future Oncol. 1(5):699–704.
   PubMedGoogle Scholar